JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

JNJ

186.77

-1.86%↓

ABT

126.59

-0.44%↓

TMO

557.87

-1.14%↓

ISRG

545.39

-0.79%↓

DHR

216.84

-1.92%↓

Search

Vivani Medical

Closed

1.67 7.05

Overview

Share price change

24h

Current

Min

1.55

Max

1.6800000000000002

Key metrics

By Trading Economics

Employees

37

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+139.52% upside

Dividends

By Dow Jones

Next Earnings

12 Nov 2025

Market Stats

By TradingEconomics

Market Cap

26M

90M

Previous open

-5.38

Previous close

1.67

Vivani Medical Chart

Past performance is not a reliable indicator of future results.

Related News

28 Oct 2025, 23:50 UTC

Hot Stocks

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 Oct 2025, 23:25 UTC

Earnings

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 Oct 2025, 23:18 UTC

Earnings

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 Oct 2025, 22:20 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 Oct 2025, 22:13 UTC

Earnings

Wal-Mart de Mexico Net Profit Falls in 3Q

28 Oct 2025, 21:38 UTC

Earnings

Correction to Visa Sales Jump Article

28 Oct 2025, 21:17 UTC

Earnings

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 Oct 2025, 21:07 UTC

Earnings

Visa Sales Jump as Consumers Keep Spending -- Update

28 Oct 2025, 21:02 UTC

Earnings

Mondelez Tempers Outlook as Costs Rise

28 Oct 2025, 23:51 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 Oct 2025, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 Oct 2025, 23:02 UTC

Earnings

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 Oct 2025, 23:01 UTC

Earnings

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 Oct 2025, 22:46 UTC

Earnings

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 Oct 2025, 22:45 UTC

Earnings

SK Hynix 3Q Net KRW12.6T >000660.SE

28 Oct 2025, 22:44 UTC

Earnings

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 Oct 2025, 22:43 UTC

Earnings

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 Oct 2025, 22:42 UTC

Earnings

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 Oct 2025, 22:40 UTC

Earnings

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 Oct 2025, 22:40 UTC

Earnings

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 Oct 2025, 22:22 UTC

Earnings

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 Oct 2025, 22:20 UTC

Earnings

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 Oct 2025, 22:02 UTC

Earnings

Review & Preview: Earnings Extravaganza -- Barrons.com

28 Oct 2025, 21:42 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

28 Oct 2025, 21:42 UTC

Market Talk
Earnings

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 Oct 2025, 21:20 UTC

Earnings

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 Oct 2025, 21:19 UTC

Earnings

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 Oct 2025, 21:18 UTC

Earnings

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Peer Comparison

Price change

Vivani Medical Forecast

Price Target

By TipRanks

139.52% upside

12 Months Forecast

Average 4 USD  139.52%

High 4 USD

Low 4 USD

Based on 2 Wall Street analysts offering 12 month price targets forVivani Medical - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Financials

$

About Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.
help-icon Live chat